Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972841 · ClinicalTrials.gov registry record · Phase 3
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 3,527
- Enrollment target
NCT01972841 is a Phase 3 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 3,527 participants.
The verdict
NCT01972841, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,527 participants
- Enrollment target
Study Summary
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
Interventions
- DRUG Mirabegron
- DRUG Solifenacin succinate
- DRUG Placebo to match mirabegron
- DRUG Placebo to match solifenacin succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,527 participants |
| Start Date | 2013-11-05 |
| Est. Completion | 2015-10-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972841
The ClinicalTrials.gov registry entry for NCT01972841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mirabegron is the first listed.
NCT01972841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01972841 about?
NCT01972841 is a clinical study titled "This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder". The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
What is the current status of trial NCT01972841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,527 participants. The study started on 2013-11-05. Estimated completion is 2015-10-22.
What interventions are being tested in trial NCT01972841?
The interventions under investigation include: Mirabegron (DRUG), Solifenacin succinate (DRUG), Placebo to match mirabegron (DRUG), Placebo to match solifenacin succinate (DRUG).
Who is sponsoring clinical trial NCT01972841?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.